Emerging & Novel Therapies

The microvascular complications of insufficiently controlled diabetes (neuropathy, retinopathy and nephropathy) and the marked increased risk of macrovascular events (e.g., stroke and myocardial infarction) have a dire impact on society in both human and economic terms. In Type 1 diabetes total β-cell loss occurs. In Type 2 diabetes, partial β-cell loss occurs before diagnosis, and the progressive β-cell loss during the life of the patient increases the severity of the disease. In patients with diabetes, increased insulin resistance in the muscle and liver are key pathophysiologic defects. In addition, defects in metabolic processes in the fat, GI tract, brain, pancreatic α-cells and kidney are detrimental to the overall health of the patient. This review addresses novel therapies for these deficiencies in clinical and preclinical evaluation, emphasizing their potential to address glucose homeostasis, β-cell mass and function, and the comorbidities of cardiovascular disease and obesity.

    Related Conference of Emerging & Novel Therapies

    September 28-29, 2018

    2nd International Conference on Diabetes and Diabetic Nursing Care

    Montreal, Quebec, Canada
    November 21-22, 2018

    14th World Congress on Endocrinology & Diabetes

    Paris, France
    November 26-27, 2018

    26th International Diabetes and Healthcare Conference

    Helsinki, Finland
    November 26-27, 2018

    13th European Diabetes and Endocrinology Congress

    Dublin, Ireland

    March 28-29, 2019

    21st Asia Pacific Diabetes Conference

    Osaka,Japan
    May 16-17, 2019

    2nd Global Meeting on Diabetes and Endocrinology

    Abu Dhabi, UAE

    28th European Diabetes Congress

    June 10-11, 2019 | Edinburgh, Scotland
    July 24-25, 2019

    29th World Diabetes & Heart Congress

    Melbourne, Australia
    Oct 03-04, 2019

    Euro Diabetes Congress & Expo

    | Paris, France

    Emerging & Novel Therapies Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in